



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) PTO FORM 1449	ATTY. DOCKET NO. 05882.0177.NPUS01	APPLICATION NO. 10/741,657
	APPLICANT LAW, et al.	
	FILING DATE December 19, 2003	GROUP 1631

U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
SK	1.	6,183,968	09-29-81					
	2.	20020142951 A1	10-03-02					
	3.	20040005563 A1	01-08-04					
	4.							

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
SK	5.	EP 0 805 204	11-05-97	Europe				X
	6.	WO 98/45436	10-15-98	PCT				
	7.	WO 00/34473	06-15-00	PCT				
	8.	EP 1 033 401	09-06-00	Europe				
	9.	WO 00/56881	09-28-00	PCT				
	10.	WO 01/54477	08-12-01	PCT				
	11.	WO 01/70979	09-27-01	PCT				
	12.	WO 02/10449	02-07-02	PCT				
	13.	WO 02/61087	08-08-02	PCT				
	14.	WO 02/79406	10-10-02	PCT				
	15.	WO 02/83856	10-24-02	PCT				
	16.	WO 02/102235	12-27-02	PCT				
	17.	WO 03/038129	05-08-03	PCT				
	18.	WO 03/051925	06-26-03	PCT				
	19.	WO 03/071272	08-28-03	PCT				
	20.	WO 02/102235	12-27-02	PCT				

1 - 12/7/06

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i> PTO FORM 1449	ATTY. DOCKET NO. 05882.0177.NPUS01	APPLICATION NO. 10/741,657
	APPLICANT LAW, et al.	
	FILING DATE December 19, 2003	GROUP 1631

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
SK	21.	Osterhoff et al., "Cloning of a Human Epididymis-Specific mRNA, HE6, Encoding a Novel Member of the Seven Transmembrane-Domain Receptor Superfamily," DNA and Cell Biology, 16: 379-389 (1997)
	22.	Obermann et al., "HE6, a Two-Subunit Heptahelical Receptor Associated with Apical Membranes of Efficient Epididymal Duct Epithelia," Molec. Reprod. & Develop. 64: 13-26 (2003)
	23.	Gilewski et al., "Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21," Clin. Cancer Res. 6:1693-1701 (2000)
	24.	Scholl et al., "Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer," J. Immunother. 23:570-580 (2000)
	25.	Bon et al., "Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays," Clin. Chem. 43:585-593 (1997)
	26.	Fitzgibbons et al., "Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999," Arch. Pathol. Lab. Med. 124:966-978 (2000)
	27.	Hamilton and Piccart, "The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2," Ann. Oncol. 11:647-663 (2000)
	28.	Robson, "Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer," J. Clin. Oncol. 18 (21 Suppl):113S-118S (2000)
	29.	GenBank accession X81892 (1996)
✓	30.	GenBank accession CAA57479 (1996)
	31.	

1 L 12/7/06

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) PTO FORM 1449	ATTY. DOCKET NO.	APPLICATION NO.
	5882.0177.NPUS01	10/741,657
	APPLICANT	
	LAW, D. <i>et al.</i> ,	
	FILING DATE	GROUP
	December 29, 2003	1631

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1.						
	2.						
	3.						
	4.						
FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO.
	5.						
	6.						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
SR	7.	International search report PCT/US03/40820					
SR	8.	Fredriksson R., <i>et al.</i> , "Novel Human G Protein-Coupled Receptors with Long N-Terminal Containing GPS domains and Ser/Thr-Rich Regions" <i>FEBS Letters</i> 531 p 407-414, (2002)					
	9.						
	10.						
	11.						
	12.						
	13.						
	14.						
	15.						
	16.						

12/7/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.